The cardioprotective actions of statins in targeting mitochondrial dysfunction associated with myocardial ischaemia-reperfusion injury

During cardiac reperfusion after myocardial infarction, the heart is subjected to cascading cycles of ischaemia reperfusion injury (IRI). Patients presenting with this injury succumb to myocardial dysfunction resulting in myocardial cell death, which contributes to morbidity and mortality. New targeted therapies are required if the myocardium is to be protected from this injury and improve patient outcomes. Extensive research into the role of mitochondria during ischaemia and reperfusion has unveiled one of the most important sites contributing towards this injury; specifically, the opening of the mitochondrial permeability transition pore. The opening of this pore occurs during reperfusion and results in mitochondria swelling and dysfunction, promoting apoptotic cell death. Activation of mitochondrial ATP-sensitive potassium channels (mitoK(ATP)) channels, uncoupling proteins, and inhibition of glycogen synthase kinase-3 beta (GSK3 beta) phosphorylation have been identified to delay mitochondrial permeability transition pore opening and reduce reactive oxygen species formation, thereby decreasing infarct size. Statins have recently been identified to provide a direct cardioprotective effect on these specific mitochondrial components, all of which reduce the severity of myocardial IRI, promoting the ability of statins to be a considerate preconditioning agent. This review will outline what has currently been shown in regard to statins cardioprotective effects on mitochondria during myocardial IRI.

Automated summary

During cardiac reperfusion after myocardial infarction, the heart faces ischaemia reperfusion injury (IRI) which leads to myocardial dysfunction and cell death. Research has identified potential targeted therapies focusing on mitochondria, such as opening of the mitochondrial permeability transition pore, activation of mitoK(ATP) channels, and inhibition of GSK3 beta phosphorylation, to reduce the severity of myocardial IRI. Additionally, statins have shown direct cardioprotective effects on specific mitochondrial components, indicating their potential as a preconditioning agent.